Bristol Myers Squibb
Last updated Jul 14, 2026
Evidence Sources
8
Competitive Findings
3
Portfolio Developments
9
Regulatory Precedents
8
Clinical Programs
3
Confidence Coverage
67%
Audit
- Competitor findings: 3
- Portfolio developments: 9
- Self-competition findings removed: 12
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Oncology
- Immunomodulator
- Hematology
- Multiple Myeloma
- Neuroscience
Highest priority development: FDA Accepts Supplemental Application for Emgality (Galcanezumab) by Eli Lilly
Portfolio development
FDA Accepts Supplemental Application for Emgality (Galcanezumab) by Eli Lilly is an owned Bristol Myers Squibb portfolio development in Neurology · CGRP Inhibitor.
Competitive pressure: Moderate
Portfolio impact: High
Evidence coverage: 67%
Active Signals
44
Investigate Priority
3
Opportunity Score
7368
Buyer Quality
10 · Enterprise
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJul 14, 2026Score 174Bristol-Myers Squibb initiates Phase 3 trial for KarXT + KarX-EC in Alzheimer's agitation
Neurology · Alzheimer's Disease
- InvestigateJun 20, 2026Score 174RBMS1 identified as a key factor in multiple myeloma malignancy and macrophage polarization
Oncology · Multiple Myeloma
- InvestigateJun 17, 2026Score 174Lactylation-related biomarker predicts prognosis and therapy response in cutaneous melanoma
Oncology · Melanoma
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
- Low Confidence · 0%Sources (3)Humanexa SignalsFDAPortfolio
- Low Confidence · 0%Sources (3)Bristol Myers SquibbFDAPortfolio
- AstraZeneca's AZD0120 Phase I Study in Multiple Myeloma InitiatedLow Confidence · 0%
Phase III success
Sources (3)Bristol Myers SquibbClinicalTrials.govPortfolio
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
- SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025Moderate Confidence · 63%
Potential competitive pressure
Sources (2)Bristol Myers SquibbCompetitiva - Gene Amplification Adjacent to F3 Linked to Poor Outcomes in Pancreatic AdenocarcinomaHigh Confidence · 88%
Limited competitive pressure indicated
Sources (2)Humanexa SignalsCompetitiva - Gene Amplification Adjacent to F3 Linked to Poor Outcomes in Pancreatic AdenocarcinomaModerate Confidence · 81%
Limited competitive pressure indicated
Sources (2)ClinicalTrials.govCompetitiva
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- Form FDA 3674 - Certifications To Accompany Drug, Biological Product, and Device Applications/SubmissionsModerate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - IND Application Reporting: IND Safety ReportsModerate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - Investigational New Drug (IND) ApplicationModerate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — INREBIC (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
- SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025Moderate Confidence · 68%
Competitive clinical program activity indicated
Sources (2)CompetitivaClinicalTrials.gov - Gene Amplification Adjacent to F3 Linked to Poor Outcomes in Pancreatic AdenocarcinomaModerate Confidence · 68%
Competitive clinical program activity indicated
Sources (2)CompetitivaClinicalTrials.gov - Gene Amplification Adjacent to F3 Linked to Poor Outcomes in Pancreatic AdenocarcinomaModerate Confidence · 68%
Competitive clinical program activity indicated
Sources (2)CompetitivaClinicalTrials.gov
Capital Markets
SEC filings, IPO activity, and capital markets events from the Business Intelligence Layer.
No capital markets intelligence is available yet.
Financing History
Venture funding, follow-on offerings, PIPE financings, and debt financing.
No financing history is available yet.
Licensing & Partnerships
Licensing agreements, strategic partnerships, and distribution deals.
No licensing or partnership activity is available yet.
M&A Activity
Acquisitions, mergers, and divestitures.
No M&A activity is available yet.
Investor Activity
Earnings releases, investor presentations, and conference appearances.
No investor activity is available yet.
Executive Changes
CEO appointments, board changes, and leadership restructuring.
No executive changes are available yet.
Business Timeline
Chronological business intelligence events across financing, licensing, M&A, and commercial strategy.
No business timeline events are available yet.
Strategic Signals
Higher-order strategic intelligence fused from regulatory, scientific, business, and competitive events. Signals answer what it means — not just what happened.
Strategic signals will appear once sufficient event convergence is detected.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
- InvestigateScore 174RBMS1 identified as a key factor in multiple myeloma malignancy and macrophage polarization
Oncology · Multiple Myeloma
- InvestigateScore 174Lactylation-related biomarker predicts prognosis and therapy response in cutaneous melanoma
Oncology · Melanoma
- InvestigateScore 168Polyploid Giant Cancer Cells Drive Aggressiveness in Ovarian Cancer and Indicate Poor Prognosis
Oncology · Ovarian Cancer
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Bristol Myers Squibb right now?
- Which regulatory precedents should Bristol Myers Squibb monitor in Oncology and Immunomodulator?
- How does Keytruda compare to the nearest competitive programs?
- What signals require immediate investigation for Bristol Myers Squibb?
- Summarize the strategic implications of recent developments for Bristol Myers Squibb.
- Where is the greatest uncertainty in Bristol Myers Squibb's competitive positioning?